Vertebroplasty In The Treatment Of Acute Fracture Trial - The VITTA Trial
NCT ID: NCT02370628
Last Updated: 2018-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
2 participants
INTERVENTIONAL
2015-04-17
2018-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The treatment offered for vertebral compression fractures (VCFs) in the interventional arm of the trial is vertebroplasty, which will be performed in accordance with the standardized protocol of the Canadian Association of Radiologists. Patients in the control arm will receive facet block, where a long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Percutaneous Vertebroplasty for Painful Acute Osteoporotic Spine Fractures
NCT01677806
VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures
NCT01643395
CT Guided Percutaneous Vertebroplasty for Vertebral Non-union Following Posterior Fixation
NCT05071625
Early Percutaneous Vertebroplasty Versus Standard Conservative Treatment in Thoracolumbar Vertebral Fractures
NCT03617094
Postrual Reduction With Pillow in Osteoporotic Vertebral Fracture
NCT03451305
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The VITTA trial is a randomized, controlled, single-blinded, cross-over trial comparing percutaneous vertebroplasty with facet block in patients with acute (\<1 month) and painful vertebral compression fractures.
Vertebral compression fractures (VCFs) frequently result in debilitating pain, impaired functional status and bad quality of life. Percutaneous vertebroplasty (PV) is a treatment for VCFs originally developed in France in the late 1980s and first performed in America in the mid-1990s. The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
VCFs are a significant public health problem with approximately 750,000 new fractures occurring in the United States each year, a number that is projected to rise as the population ages. In fact, one quarter of adults over the age of 50 will suffer at least one VCF in their lifetime. VCFs cause short term and occasionally long-term pain and disability, and although not immediately life threatening, they are associated with long term mortality. Before the advent of PV, the treatment for VCFs was limited to medical therapy- addressing the pain associated with the fracture but not the fracture itself thus making VCFs practically the only skeletal fracture not treated with orthopedic surgery. Since the introduction of vertebroplasty, over 800 papers, technical notes, and reviews that address this technique have been published with the overwhelming majority reporting significant pain relief and advocating the adoption of the procedure into common practice. Unfortunately, most of these studies had low evidence level and poor scientific design until randomized clinical trials were published in 2009.
Vertebroplasty for refractory back pain (after a period of conservative management of 1 month) constituted the main indication in the overwhelming majority of studies published so far. Although those studies have largely suggested that it does not offer significant improvement in pain or functional status relative to medical therapy or infusion of local anesthesia after this acute phase, the data remains inconclusive and of poor scientific quality. The present study proposes a different rationale: the benefits of vertebroplasty may be occurring in the acute phase (before 1 month) by providing immediate pain relief to the patient, hence allowing early mobilization and preventing medical complications associated with bed rest. In other terms, vertebroplasty may be a first line, acute phase treatment. If the investigators hypothesis holds true, an adequately powered clinical trial may provide sufficient evidence to change the medical indications for vertebroplasty.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Percutaneous vertebroplasty (PV)
The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
Percutaneous vertebroplasty
The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.
In our trial, vertebroplasty shall be performed in two steps:
* Step 1: facet block
* Step 2: cement infusion
Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention.
Facet block
A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.
All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty.
Facet block
injection of anti-inflammatory and analgesic drugs
Facet block
A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.
All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Percutaneous vertebroplasty
The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.
In our trial, vertebroplasty shall be performed in two steps:
* Step 1: facet block
* Step 2: cement infusion
Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention.
Facet block
A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.
All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of:
* at least one and at most two acute VCF (\< 6 weeks) at levels caudate to T4, confirmed with physical examination and radiographic imaging
* if timing of the fracture is unclear, the following criteria are required for inclusion in the trial
1. an MRI scan showing edema at the fracture level(s) or
2. a bone scan showing increased uptake
* Physical examination showing axial back pain likely secondary to the VCF with restricted mobilization (score not maximum on any one of the following Barthel's Index items: transfer, mobility, bathing, dressing, stairs and toilet use)
* French or English speaking patient willing to return for follow-up or capable of following up with phone interviews if needed
Exclusion Criteria
* Coagulopathy or thrombocytopenia precluding interventional treatment
* Inability to provide informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Raymond, MD
Role: PRINCIPAL_INVESTIGATOR
CHUM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bourgoin P, Weill A, Tampieri D. CAR Standard for Performance of the Percutaneous Vertebroplasty. Can Assoc Radiol. 2002;(March).
Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med. 2009 Aug 6;361(6):569-79. doi: 10.1056/NEJMoa0900563.
Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009 Aug 6;361(6):557-68. doi: 10.1056/NEJMoa0900429.
Comstock BA, Sitlani CM, Jarvik JG, Heagerty PJ, Turner JA, Kallmes DF. Investigational vertebroplasty safety and efficacy trial (INVEST): patient-reported outcomes through 1 year. Radiology. 2013 Oct;269(1):224-31. doi: 10.1148/radiol.13120821. Epub 2013 May 21.
Voormolen MH, Mali WP, Lohle PN, Fransen H, Lampmann LE, van der Graaf Y, Juttmann JR, Jansssens X, Verhaar HJ. Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study. AJNR Am J Neuroradiol. 2007 Mar;28(3):555-60.
Do HM, Kim BS, Marcellus ML, Curtis L, Marks MP. Prospective analysis of clinical outcomes after percutaneous vertebroplasty for painful osteoporotic vertebral body fractures. AJNR Am J Neuroradiol. 2005 Aug;26(7):1623-8.
Deramond H, Darrason R GP. Percutaneous vertebroplasty with acrylic cement in the treatment of aggressive spinal angiomas. Rachis. 1989;1(2):143-53.
Jensen ME, Evans AJ, Mathis JM, Kallmes DF, Cloft HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol. 1997 Nov-Dec;18(10):1897-904.
Deramond H, Depriester C, Galibert P, Le Gars D. Percutaneous vertebroplasty with polymethylmethacrylate. Technique, indications, and results. Radiol Clin North Am. 1998 May;36(3):533-46. doi: 10.1016/s0033-8389(05)70042-7.
Gangi A, Guth S, Imbert JP, Marin H, Dietemann JL. Percutaneous vertebroplasty: indications, technique, and results. Radiographics. 2003 Mar-Apr;23(2):e10. doi: 10.1148/rg.e10.
Gu YF, Li YD, Wu CG, Sun ZK, He CJ. Safety and efficacy of percutaneous vertebroplasty and interventional tumor removal for metastatic spinal tumors and malignant vertebral compression fractures. AJR Am J Roentgenol. 2014 Mar;202(3):W298-305. doi: 10.2214/AJR.12.10497.
Chen G, Luo ZP, Zhang H, Nalajala B, Yang H. Percutaneous kyphoplasty in the treatment of painful osteoblastic metastatic spinal lesions. J Clin Neurosci. 2013 Jul;20(7):948-50. doi: 10.1016/j.jocn.2012.08.010. Epub 2013 May 3.
Pereira LP, Clarencon F, Cormier E, Rose M, Jean B, Le Jean L, Chiras J. Safety and effectiveness of percutaneous sacroplasty: a single-centre experience in 58 consecutive patients with tumours or osteoporotic insufficient fractures treated under fluoroscopic guidance. Eur Radiol. 2013 Oct;23(10):2764-72. doi: 10.1007/s00330-013-2881-3. Epub 2013 May 21.
Weill A, Chiras J, Simon JM, Rose M, Sola-Martinez T, Enkaoua E. Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement. Radiology. 1996 Apr;199(1):241-7. doi: 10.1148/radiology.199.1.8633152.
Chiras J, Depriester C, Weill A, Sola-Martinez MT, Deramond H. [Percutaneous vertebral surgery. Technics and indications]. J Neuroradiol. 1997 Jun;24(1):45-59. French.
Ruiz Santiago F, Santiago Chinchilla A, Guzman Alvarez L, Perez Abela AL, Castellano Garcia Mdel M, Pajares Lopez M. Comparative review of vertebroplasty and kyphoplasty. World J Radiol. 2014 Jun 28;6(6):329-43. doi: 10.4329/wjr.v6.i6.329.
Yimin Y, Zhiwei R, Wei M, Jha R. Current status of percutaneous vertebroplasty and percutaneous kyphoplasty--a review. Med Sci Monit. 2013 Oct 7;19:826-36. doi: 10.12659/MSM.889479.
Liu J, Li X, Tang D, Cui X, Li X, Yao M, Yu P, Qian X, Wang Y, Jiang H. Comparing pain reduction following vertebroplasty and conservative treatment for osteoporotic vertebral compression fractures: a meta-analysis of randomized controlled trials. Pain Physician. 2013 Sep-Oct;16(5):455-64.
Fotiadou A, Wojcik A, Shaju A. Management of low back pain with facet joint injections and nerve root blocks under computed tomography guidance. A prospective study. Skeletal Radiol. 2012 Sep;41(9):1081-5. doi: 10.1007/s00256-011-1353-6. Epub 2012 Jan 10.
Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Fellows B. Complications of fluoroscopically directed facet joint nerve blocks: a prospective evaluation of 7,500 episodes with 43,000 nerve blocks. Pain Physician. 2012 Mar-Apr;15(2):E143-50.
Melton LJ 3rd. Epidemiology of spinal osteoporosis. Spine (Phila Pa 1976). 1997 Dec 15;22(24 Suppl):2S-11S. doi: 10.1097/00007632-199712151-00002.
Jones G, White C, Nguyen T, Sambrook PN, Kelly PJ, Eisman JA. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int. 1996;6(3):233-9. doi: 10.1007/BF01622740.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009 Feb 4;301(5):513-21. doi: 10.1001/jama.2009.50.
Rousing R, Andersen MO, Jespersen SM, Thomsen K, Lauritsen J. Percutaneous vertebroplasty compared to conservative treatment in patients with painful acute or subacute osteoporotic vertebral fractures: three-months follow-up in a clinical randomized study. Spine (Phila Pa 1976). 2009 Jun 1;34(13):1349-54. doi: 10.1097/BRS.0b013e3181a4e628.
Diamond TH, Bryant C, Browne L, Clark WA. Clinical outcomes after acute osteoporotic vertebral fractures: a 2-year non-randomised trial comparing percutaneous vertebroplasty with conservative therapy. Med J Aust. 2006 Feb 6;184(3):113-7. doi: 10.5694/j.1326-5377.2006.tb00148.x.
Alvarez L, Alcaraz M, Perez-Higueras A, Granizo JJ, de Miguel I, Rossi RE, Quinones D. Percutaneous vertebroplasty: functional improvement in patients with osteoporotic compression fractures. Spine (Phila Pa 1976). 2006 May 1;31(10):1113-8. doi: 10.1097/01.brs.0000216487.97965.38.
Whitley E, Ball J. Statistics review 4: sample size calculations. Crit Care. 2002 Aug;6(4):335-41. doi: 10.1186/cc1521. Epub 2002 May 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CE14.334
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.